DRRX Stock 2.03 Durect Corp $DRRX Hit 12,933 52 week highs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 239

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 129

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 81

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 152

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 375

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 188

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 35

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Booming Healthcare Asset Management Market

Updated Category News Views 189

Healthcare Asset Management Market Overview The Healthcare Asset Management market has been experiencing remarkable growth, with projections estimating its value to exceed USD 166.82 billion. This rapid expansion is driven by an impressive compound annual growth rate (CAGR) of 23.1% from 2024 to 2032. This article delves into the reasons behind this growth and what the...

Continue Reading
Chijet Motor Company Partners with EdgeAI for Token Acquisition

Updated Category News Views 133

Chijet Motor Company Announces Strategic Partnership Chijet Motor Company, Inc. (NASDAQ: CJET), proudly unveils its agreement with EdgeAI Frontier Technology Ltd. This partnership aims to secure up to $1 billion in EdgeAI tokens at a remarkable 20% discount off current market prices. This strategic collaboration transcends traditional operations, marking a significant...

Continue Reading
Myriad Genetics Navigates Market Trials Following Stock Dip

Updated Category News Views 138

Myriad Genetics Faces Market Challenges Myriad Genetics, Inc. (NASDAQ: MYGN) has recently hit a new 52-week low, marking a critical moment for the company with stock prices plummeting to $12.16. This decline highlights a tough market landscape for the firm, which specializes in genetic testing and precision medicine. Over the last six months, the stock has seen a...

Continue Reading
Veriff Expands into Latin America, Driving Global Identity Solutions

Updated Category News Views 184

Veriff Expands into Latin America Veriff, a pioneering company in AI-driven identity verification, is excited to announce its recent expansion into Latin America with the opening of a new headquarters in Brazil. This strategic initiative comes as part of Veriff's growth strategy, following exceptional increases in business volumes in the region, noted at more than two and...

Continue Reading
Analysts Adjust Predictions for Lam Research’s Upcoming Earnings

Updated Category News Views 125

Overview of Lam Research Earnings Anticipation Lam Research Corporation (NASDAQ:LRCX) is on the cusp of announcing its earnings for the first quarter. This significant moment is eagerly awaited by investors and analysts alike, particularly following a year of notable growth. Current estimates suggest that Lam Research is set to report earnings of $1.22 per share, a jump...

Continue Reading